Sherrington Pharmaceuticals, Sorrento deal

Sorrento acquired Sherrington for 200,000 Sorrento shares in a deal that valued Sherrington at $1.6 million based on Sorrento's close of $7.80 on Oct. 9, before the deal was announced. Sorrento will gain Sherrington's Resiniferatoxin, a selective agonist of transient receptor potential vanilloid 1 ( TRPV1; VR1) that is in an NIH-sponsored Phase I/II trial to treat chronic pain in end-stage cancer patients. ...